

**CTSU SCUSF 0806** - Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with trastuzumab (Herceptin®)

***Fast Facts***

CTC v.4

Lisinopril and Coreg CR provided

**Inclusion Criteria:**

1. Females  $\geq$  18 years old diagnosed with HER2 positive breast cancer
2. Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted). Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up. Taxanes are permitted. Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy.
3. Left Ventricular Ejection Fraction (LVEF)  $\geq$  50% by MUGA scan or echocardiogram
4. Normal renal function defined as creatinine  $\leq$  1.2 mg/dL
5. Sitting systolic blood pressure of  $>$  90 mm Hg
6. Pulse  $\geq$  60 beats/minute
7. Not pregnant or breastfeeding
  - a. Patients of childbearing potential, who are sexually active, must have a negative pregnancy test before starting the study, and be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents
8. Able to swallow capsules
9. Able and willing to give informed consent
10. Signed HIPAA compliant research authorization (or equivalent for international sites) to release Personal Health Information to the SunCoast CCOP Research Base.

**Exclusion criteria:**

1. Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen
2. Current treatment with angiotensin converting enzyme (ACE) inhibitors,  $\beta$ - blockers or digoxin
3. Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction
4. Known allergy to either ACE inhibitors or  $\beta$ -blockers
5. History of bronchial asthma or related bronchospastic conditions
6. Hereditary or idiopathic angioedema
7. History of severe hypersensitivity reactions to drugs or other causes, i.e. bee stings
8. This protocol does not exclude patients who are participating on other investigational studies. Refer to the local IRB guidelines.

**Pre-Study Parameters**

1. History and physical including height and weight, performance status, and concomitant medication assessment
2. Labs including CMP, pregnancy test; Blood collection for BNP and Troponin I to be analyzed by sponsor for research purposes.
3. MUGA or Echo

**Treatment** – this is a double blind, placebo controlled trial

<u>Agent (dose)</u>	<u>Route</u>	<u>Frequency</u>
Lisinopril (10 mg) or Coreg (10 mg) or placebo	PO	Daily while receiving Herceptin therapy

Patients will have LVEF assessment every 3 months +/- 2 weeks during Herceptin therapy for a year and at 3 and 6 months post Herceptin therapy.